Brokerages Anticipate Aileron Therapeutics Inc (NASDAQ:ALRN) to Announce -$0.10 Earnings Per Share

Share on StockTwits

Equities analysts expect that Aileron Therapeutics Inc (NASDAQ:ALRN) will report ($0.10) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.10). Aileron Therapeutics posted earnings of ($0.28) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 64.3%. The firm is expected to announce its next quarterly earnings report on Thursday, November 5th.

On average, analysts expect that Aileron Therapeutics will report full year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.54). For the next fiscal year, analysts expect that the business will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.74) to ($0.36). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05.

A number of research firms recently weighed in on ALRN. HC Wainwright reissued a “buy” rating on shares of Aileron Therapeutics in a research note on Tuesday, August 4th. Zacks Investment Research lowered shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. William Blair reissued a “buy” rating on shares of Aileron Therapeutics in a research note on Monday, August 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Aileron Therapeutics in a research note on Tuesday, June 2nd.

NASDAQ:ALRN traded up $0.01 on Tuesday, hitting $1.16. 444,147 shares of the stock were exchanged, compared to its average volume of 536,598. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.99 and a current ratio of 3.99. Aileron Therapeutics has a 52 week low of $0.25 and a 52 week high of $1.99. The stock has a market capitalization of $45.54 million, a price-to-earnings ratio of -1.26 and a beta of 3.65. The company’s 50-day moving average price is $1.17 and its 200 day moving average price is $0.85.

In other news, Director Rickenbach Josef H. Von bought 227,272 shares of the stock in a transaction on Monday, June 8th. The stock was purchased at an average price of $1.10 per share, with a total value of $249,999.20. Following the completion of the purchase, the director now owns 445,460 shares of the company’s stock, valued at $490,006. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.20% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $28,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aileron Therapeutics during the second quarter worth $29,000. Geode Capital Management LLC lifted its position in Aileron Therapeutics by 67.1% in the 4th quarter. Geode Capital Management LLC now owns 91,895 shares of the company’s stock valued at $52,000 after acquiring an additional 36,893 shares in the last quarter. Finally, Personal CFO Solutions LLC boosted its stake in Aileron Therapeutics by 106.0% in the 2nd quarter. Personal CFO Solutions LLC now owns 47,388 shares of the company’s stock worth $56,000 after purchasing an additional 24,388 shares during the period. 9.94% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: What are retained earnings?

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply